Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)
Blood（2021）
Abstract
Introduction
MoreTranslated text
Key words
relapsed/refractory myelofibrosis,navtemadlin,disease-modifying,first-in-class
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined